Superpower peptides available for pre-order. Get first access.
Not FDA-approved
Brain & sleep
What are the side effects of epitalon?
See what FDA's 2026 review and published studies report on epitalon side effects, product quality, and when to call a clinician.
Quick answer
Epitalon is not FDA-approved and has no established labeled route. It has no established human side-effect profile. Safety data come mostly from animal studies and three small human studies of 15, 20, and 162 people. FDA found no epitalon adverse-event reports through December 8, 2025. Spreading redness or fever near an injection site warrants a call to the prescribing clinician. Wheezing or facial swelling needs emergency care.
- Published
- November 4, 2026
- Last updated
- November 4, 2026
What to know about epitalon side effects
Epitalon, also spelled epithalon, has no established human side-effect profile. Most published epitalon safety findings come from animal research. Human data come from three small, older studies1. Epitalon is a synthetic peptide, chemically distinct from epithalamin1, a pineal-gland extract. Research on the extract does not describe epitalon.
What epitalon side effects have been reported?
No specific epitalon side effects are on record with FDA. Its database searches came back empty through December 20252.
The FDA Adverse Event Reporting System retrieved no epitalon reports through December 8, 20252. The Human Foods Complaint System retrieved no cases through December 5, 20252.
Adverse-event reporting is voluntary, and FDA does not receive every report2, especially for compounded products. Compounding pharmacies generally do not file these reports. FDA states it cannot make definitive safety conclusions from FAERS data alone.
What do studies show about epitalon safety?
Several animal studies of epitalon reported no overt harm1.
Female mice given subcutaneous (under-the-skin) epitalon five days a month3 for life showed no change in mean lifespan or overall tumor incidence. That result is part of why epitalon is often described as well tolerated. The mice received one fixed dose in short, intermittent courses2. The result describes those animals rather than a human safety profile.
Three small human studies1 gave epitalon by injection into muscle to 15 older adults, under the tongue to 20 women, and by injection around the eye to 162 people. The studies described no adverse effects. None was designed as a dedicated safety study1.
A product made today may differ from the epitalon those researchers used.
Epitalon product quality and safety
The product itself is part of epitalon safety. Compounded drugs are not FDA-approved4, so FDA does not check their quality before sale.
- Strength and purity: Epitalon's chemical identity does not guarantee a product's purity, concentration, or stability1, and FDA found the ingredient not well characterized2.
- Sterility: FDA found microbial-quality and bacterial-toxin data lacking, and sterility, bacterial toxins, and particles are critical safety factors for injected epitalon2.
- Immune reactions: Clumped peptide and impurities in epitalon products may trigger immune responses5, which can range from symptom-free antibodies to life-threatening reactions2.
- Storage: FDA expects epitalon to stay stable when stored below -4°F (-20°C)2.
Early signs of a reaction are worth knowing.
How can epitalon side effects be managed?
Managing epitalon side effects starts with calling the prescribing clinician about any new symptom. Signs of a severe allergic reaction call for emergency care instead6.
- Watch the injection site: Skin infection around an epitalon injection can bring redness that spreads, warm skin, and tenderness7, sometimes with fever.
- Write it down: Noting the symptom's timing, the epitalon product, and the route helps the prescribing clinician judge it.
- Contact the prescribing clinician: Infection signs need a provider's attention right away7, and anyone can report a reaction to FDA's MedWatch program8.
- Get emergency care: Wheezing, chest tightness, hives, facial swelling, or a swollen tongue can develop within minutes6 and need 911 or the nearest emergency room.
Some epitalon risks are better discussed before a first dose.
Who should talk to a clinician first?
A few health situations are worth reviewing with the prescribing clinician before starting epitalon. These reasons come from evidence gaps and lab or animal signals, not proven harms in people.
| Before using epitalon, discuss | Why it matters |
| Pregnancy or breastfeeding | FDA found no developmental or reproductive toxicity studies2, and a rabbit study detected labeled epitalon in fetal organs, a result FDA says to interpret with caution |
| Cancer history or unexplained growths | Epitalon lengthened telomeres in breast cancer cell lines9 (telomeres are the protective caps on chromosome ends); genetically longer telomeres are linked to several cancers10; and FDA flags a potential cancer risk on mechanistic grounds2, which together make a case for individual risk review |
| Past allergic reactions to peptides or medicines | A history of any allergic reaction raises the risk of anaphylaxis6 (a severe allergic reaction), and FDA has flagged immune-reaction concerns about injected epitalon2 |
| Other medicines and supplements | FDA found no pharmacokinetic data for epitalon2 (how the body absorbs and clears a drug), so how epitalon behaves alongside other medicines has not been measured |
The prescribing clinician weighs each one against a person's own history.
Getting epitalon in 2026
Superpower will offer epitalon formulated in FDA-registered facilities in the US, backed by third-party lab testing, and distributed from US-licensed pharmacies. A licensed clinician will review each person's health history to decide whether epitalon fits their health care. The Superpower peptide waitlist is open now.
Epitalon is not an FDA-approved drug; access currently depends on an interim federal policy. In October 2026, the Department of Health and Human Services said it does not intend to take enforcement action11 against state-licensed pharmacies compounding certain peptides while the 503A Bulks List, the list of ingredients pharmacies may use in compounding, is finalized. Epitalon is one of six peptides covered12, with conditions including ingredients from FDA-registered facilities and a patient-specific prescription. A July 2026 FDA advisory committee had recommended adding epitalon to the list13, and rulemaking continues.